A meeting of the Commercial Product Delivery Committee of the Citrus Research and Development Foundation, Inc. was held on Tuesday, August 18, 2015 at the Grove House on Hwy. 27 in Lake Wales, Florida. The meeting was properly noticed and recorded. The meeting was called to order at 9:30 am by Chairman Ben McLean. Roll was called and a quorum was present. Committee members participating were: Dr. Timothy L. Anglea; Mr. Larry Black; Mr. Joe L. Davis, Jr.; Mr. Ben McLean; Mr. Jerry Newlin; Mr. Andy Rackley; and Ms. Shannon Shepp. Committee members Dr. Mary L. Duryea; Mr. David Howard; Mr. Ricke Kress; Mr. Peter McClure; Mr. Tom Stopyra and Mr. Hugh Thompson did not participate. Also participating were Mr. Dan Botts (telephone), Dr. Bob Bruss, Dr. Jim Dukowitz and Dr. Stephanie Slinski.

Others attending the meeting included Mr. Kevin Bouffard, Mr. Jason Carlton, Dr. Lisa Conti (telephone), and Mr. Wayne Dubberly. Mr. Horace Durance, Ms. Brandi Goller, Mr. Marty McKenna, Mr. Trevor Murphy, Mr. Rusty Noah, Ms. Audrey Nowicki, Mr. Mike Sanders, Mr. Bill Sheffield, Mr. Gary Simmons, Ms. Callie Walker, Mr. Mark Watters, and Mr. Jed Weeks.

Mr. Davis moved to accept the minutes of the June 12, 2015 meeting. The motion was seconded by Mr. Black and passed unanimously.

Mr. Botts gave an update of the strategy for moving bactericides to regulatory consideration, a process started after hearing project updates by AgroSource, Inc. and NuFarm Americas, Inc. at the July 28th Executive Committee meeting. He reviewed the requirements for initiating the application to FDACS and movement to the EPA. Currently field data is being compiled that is a major component of the application. Mr. Botts outlined the action plan in a proposal from Third Party Registrations, Inc. Mr. Newlin made a motion to ratify the actions taken to date by Mr. Botts toward the registration and to encourage continuation. Seconded by Mr. Davis, the motion passed unanimously.

Dr. Bruss updated the committee on NuFarm Americas, Inc.’s progress on their project for a Section 18 label on Mycoshield.

Dr. Slinski and Dr. Dukowitz highlighted progress on the Commercial Product Delivery projects as reported in the June 30th Quarterly Progress Report which was included with the meeting materials. A summary from Dr. Santra was distributed outlining advances made on CRDF-funded research projects between 2009 and 2015.

With no further business, the meeting was adjourned at 11:50 am.

Minutes submitted by Audrey Nowicki